The Ataxia-Telangiectasia market may be offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access, and reimbursement issues, and a scarcity of healthcare specialists.
DelveInsight’s “Ataxia Telangiectasia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ataxia Telangiectasia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Ataxia Telangiectasia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Ataxia Telangiectasia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Ataxia Telangiectasia: An Overview
Ataxia telangiectasia (AT) is a complex genetic neurodegenerative disorder that may become apparent during infancy or early childhood. The disorder is characterized by progressively impaired coordination of voluntary movements (ataxia), the development of reddish lesions of the skin and mucous membranes due to permanent widening of groups of blood vessels (telangiectasia), and impaired functioning of the immune system (i.e., cellular and humoral immunodeficiency), resulting in increased susceptibility to upper and lower respiratory infections (sinopulmonary infections).
Individuals with Ataxia Telangiectasia also have an increased risk of developing certain malignancies, particularly of the lymphatic system (lymphomas), the blood-forming organs (e.g., leukemia), and the brain. Ataxia telangiectasia is inherited as an autosomal recessive trait. Genetic diseases are determined by genes received from the parents.
In those with Ataxia Telangiectasia, progressive ataxia typically develops during infancy and may initially be characterized by abnormal swaying of the head and trunk. As the disease progresses, the condition leads to an inability to walk (ambulation) by late childhood or adolescence. Ataxia is often accompanied by difficulty speaking (dysarthria), drooling; and an impaired ability to coordinate certain eye movements (oculomotor apraxia), including the occurrence of involuntary, rapid, rhythmic motions (oscillations) of the eyes while attempting to focus upon certain objects (fixation nystagmus).
Ataxia Telangiectasia Market Key Facts
-
According to a study by Giulietta et al. (2021), in the United States, about 1% of the population is a carrier of a mutation in the Ataxia-Telangiectasia mutated kinase (ATM) gene.
-
As per the National Library of Medicine (2018), Ataxia-Telangiectasia occurs in 1 in 40,000–100,000 people worldwide.
-
As per Jayesh et al. (2015), the prevalence of patients with Ataxia-Telangiectasia in Europe was estimated to be 1 per 150,000.
-
As per Chessa et al. (2016), clinical manifestations of Ataxia-Telangiectasia are neurological manifestations, immunodeficiency (33% of people with A-T), pulmonary disease (25% of people), and cancer (25% risk of cancer).
-
The pipeline of Ataxia-Telangiectasia is not very robust, only a few potential therapies are being investigated for the treatment of Ataxia-Telangiectasia, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Ataxia Telangiectasia pipeline therapies. It also thoroughly assesses the Ataxia Telangiectasia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Ataxia Telangiectasia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Ataxia Telangiectasia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Ataxia Telangiectasia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Ataxia Telangiectasia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Ataxia Telangiectasia Epidemiology, Segmented as –
-
Total Prevalent Cases of Ataxia-Telangiectasia in the 7MM (2019–2032)
-
Diagnosed and Treatable Cases of Ataxia Telangiectasia in the 7MM (2019–2032)
Ataxia Telangiectasia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Ataxia Telangiectasia market or expected to be launched during the study period. The analysis covers the Ataxia Telangiectasia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Ataxia Telangiectasia drugs based on their sale and market share.
The report also covers the Ataxia Telangiectasia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Ataxia Telangiectasia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Ataxia Telangiectasia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market
Ataxia Telangiectasia Therapeutics Analysis
Currently, there is no approved drug therapy or cure for the treatment of Ataxia-Telangiectasia. Treatment is based on the severity of the disease and the available treatment approaches are symptomatic and supportive.
Therapeutic drugs being used in the treatment of Ataxia-Telangiectasia include antibiotics, vaccines (Streptococcus pneumonia, Neisseria meningitides, Hemophilus influenza), Immunoglobulin, Neuroprotective Treatments (Antioxidants (vitamin E or a-lipoic acid)), Antiepileptic drugs and Glucocorticoids. The drug Diazepam (Valium) may be useful in some cases to help slurred speech and involuntary muscle contractions.
To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Ataxia Telangiectasia. Currently, Matrix Biomed is leading the therapeutics market with its Ataxia Telangiectasia drug candidates in the most advanced stage of clinical development.
Ataxia Telangiectasia Companies Actively Working in the Therapeutics Market Include
-
Matrix Biomed
-
IntraBio Inc
-
EryDel
-
Acasti Pharma
And Many Others
Emerging and Marketed Ataxia Telangiectasia Therapies Covered in the Report Include:
-
MBM-01: Matrix Biomed
-
IB-1001: IntraBio Inc
-
EryDex: Erydel
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Ataxia Telangiectasia Competitive Intelligence Analysis
4. Ataxia Telangiectasia Market Overview at a Glance
5. Ataxia Telangiectasia Disease Background and Overview
6. Ataxia Telangiectasia Patient Journey
7. Ataxia Telangiectasia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Ataxia Telangiectasia Treatment Algorithm, Current Treatment, and Medical Practices
9. Ataxia Telangiectasia Unmet Needs
10. Key Endpoints of Ataxia Telangiectasia Treatment
11. Ataxia Telangiectasia Marketed Therapies
12. Ataxia Telangiectasia Emerging Drugs and Latest Therapeutic Advances
13. Ataxia Telangiectasia Seven Major Market Analysis
14. Attribute Analysis
15. Ataxia Telangiectasia Market Outlook (In US, EU5, and Japan)
16. Ataxia Telangiectasia Companies Active in the Market
17. Ataxia Telangiectasia Access and Reimbursement Overview
18. KOL Views on the Ataxia Telangiectasia Market
19. Ataxia Telangiectasia Market Drivers
20. Ataxia Telangiectasia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Gastro-Intestinal Bleeding Market
“Gastro-Intestinal Bleeding Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Gastro-Intestinal Bleeding market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Gastro-Intestinal Bleeding market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/